Navigation Links
Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track
Date:11/1/2007

e 2 clinical studies.

On August 15, 2007, following the expiry of the Hart-Scott-Rodino waiting period, Shire's agreement with Renovo became effective. Under the terms of this agreement, Shire has exclusive rights to commercialize JUVISTA worldwide (with the exception of EU member states). Shire paid Renovo a $75 million up-front payment in respect of the license (expensed during this quarter as R&D) and made a $50 million equity investment in Renovo (at a subscription price of GBP2 per ordinary share, representing approximately 6.5% of Renovo's share capital). Shire's future financial obligations under the agreement are geared to the successful development and commercialization of JUVISTA.

VYVANSE - ADHD

During Q3 2007, the FDA accepted the filing of a supplemental New Drug Application for VYVANSE for the treatment of ADHD in adults. The Prescriptions Drug User Fee Act action date ("PDUFA date") is April 28, 2008. On October 25, 2007 Shire released results from the Phase 3 clinical trials in adults. In this double-blind, placebo-controlled, four-week study with dose escalations in 414 adults aged 18 to 55 years, treatment with VYVANSE at all doses studied (30 mg, 50 mg, 70 mg) was significantly more effective than placebo.

Shire is expecting a decision from the FDA on the approvability of VYVANSE intermediate strength products in the pediatric indication by the PDUFA date, December 15, 2007. If approved, this would make 20mg, 40mg and 60mg product available, which are designed to increase the flexibility of the dosing of VYVANSE for the pediatric indication in the US.

SPD493 (formerly known as Valrocemide)

Following preclinical evaluation, Shire intends to study SPD493 in a number of Central Nervous Systems disorders, and Phase 1 clinical trials started in October 2007.

Q3 2007 Unaudited Results

Q3 2007 Q3 2006

Non
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. Further support for use of statins in Alzheimer’s disease
2. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
3. Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered
4. NHS announces further Cost cutting Measures
5. NHS Recommends Further Cost Cutting Measures
6. Medha Patkars Condition Deteriorates Further
7. Oxford Radcliffe Hospitals Warns Of Further Job Losses
8. Asia Arming up to further the AIDS fight
9. Further Studies Needed To Completely Understand About Ventricular Fibrillation
10. Further improvements envisaged at Carstairs
11. UCLA Find Yields Further Insight into Causes of Parkinson’s Diseas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... 01, 2014 An operating theatre or ... for performing surgical operations. An operating room comprises a ... booms, operating room lights, imaging displays as well as ... by Transparency Market Research, a U.S.-based market research firm, ... USD 4.5 billion by 2019. , According to ...
(Date:9/1/2014)... September 2014: Daily fruit consumption cuts the risk of ... research presented at ESC Congress today by Dr Huaidong ... year follow-up study of nearly 0.5 million people in ... people ate, the more their risk of CVD declined. ... (IHD) and stroke, is the leading cause of death ...
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 ... store, retrieve, organize and analyze biological and genetic ... of the activity of developing software tools to ... not to be confused with biological computation. While ... better understanding of biology can its related concepts, ...
(Date:9/1/2014)... September 01, 2014 Ontraport , ... marketers that was developed to automate the small intricacies ... attention of Shane Michaels, prompting an investigative review. ... daily duty of managing all of the small details ... quite overwhelming,” reports Michaels. “That’s why Ontraport has become ...
(Date:9/1/2014)... Aliso Viejo, California (PRWEB) September 01, 2014 ... of a new tutorial video for the ProWorld Plugin from ... what Final Cut Pro X can do and users now ... own HDRI images.” Said Christina Austin, CEO of Pixel Film ... a definite game changer.” , Learn how to turn a ...
Breaking Medicine News(10 mins):Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:Pixel Film Studios Released a New Tutorial Entitled ProWorld Lesson Exclusively for Final Cut Pro X 2
... (HealthDay News) -- Scientists say they,ve learned why a ... bland supermarket variety. The University of Florida researchers ... heirloom varieties, most of which were bred before today,s ... large chemical diversity. The researchers than had ...
... News) -- Women with advanced breast cancer who have higher ... women with lower levels of fitness during treatment, new research ... and lung function, according to the study by researchers at ... years after treatment has ended. Among those with advanced ...
... News) -- Only one in 14 Hispanic adults in the ... fewer than the one in four whites screened, a new ... insurance and poorer access to health care services are major ... Cancer Institute of New Jersey. They added that their ...
... from the University of California, San Diego and its ... in new grants from the California Institute for Regenerative ... spinal cord injuries, repairing gene mutations that cause amyotrophic ... failure and Alzheimer,s disease. The awards mark the ...
... An overactive BAALC gene in acute leukemia cells identifies patients ... This study discovered why the gene is often overactive., ... guide therapy in these patients. COLUMBUS, Ohio ... overactivating a gene linked to poor treatment response in people ...
... YORK, May 25, 2012 Ben-Gurion University of the ... the desert with the successful application of a solar-powered ... regions. The project was made possible with support from ... The solar-powered system uses nanofiltration membranes to treat the ...
Cached Medicine News:Health News:Fitness May Boost Survival for Women With Breast Cancer 2Health News:Few U.S. Hispanics Screened for Skin Cancer 2Health News:UC San Diego researchers receive new CIRM funding 2Health News:UC San Diego researchers receive new CIRM funding 3Health News:Inherited DNA change explains overactive leukemia gene 2Health News:Ben-Gurion U. researchers successfully test solar desalination system for arid land agriculture 2
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
(Date:8/29/2014)... Md. , Aug. 29, 2014  United Therapeutics ... the U.S. District Court for the District of ... favor in the company,s case against Sandoz, Inc. regarding ... Peter Sheridan ruled that U.S. Patent No. ... and enjoined Sandoz from marketing its generic product until ...
(Date:8/29/2014)...  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... to release its financial results for the fiscal 2014 ... market trading ends on Tuesday, September 9, 2014. ... 4:30 p.m. U.S. EDT on Tuesday, September 9, 2014 ... the Company,s financial results, commercial partnerships, and future outlook.  ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... 2011 Express Scripts (Nasdaq: ESRX ), one ... announced today its intention to release its third quarter earnings ... will hold its quarterly conference call to discuss third quarter ... Time (8:30 a.m. Central Time). This call is ...
... U.S. Food and Drug Administration has issued a proposed ... classification for external pacemaker pulse generators from Class III ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) External pacemaker pulse generators are ... permanent pacemaker can be implanted. They are also used ...
Cached Medicine Technology:FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers 2FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers 3
Curved shafts with 0.5 mm, 1 x 2 teeth. Serrated handle with thumb catch lock and polished finish....
Narrow 12 mm jaws with fine teeth. Serrated handle with polished finish....
Straight shafts with heavy Elschnig teeth. Flat serrated handle with slide style lock and polished finished....
Straight shafts with delicate 0.7 mm, 1 x 2 teeth. Serrated handle with polished finish....
Medicine Products: